NovaBridge Biosciences (NASDAQ:NBP) and IMab (NASDAQ:IMAB) Analyst Ratings and Outlook

NovaBridge Biosciences has seen a slight decrease in its consensus price target, moving from $7.75 to $7.00.IMab received an upgrade to a Zacks Rank #2 (Buy), with a new price target set at $8.00 by analyst Kumaraguru Raja.Both companies are in the biotech sector, focusing on different aspects of medical research and development, indicating varied analyst outlooks based on recent developments.NovaBridge Biosciences (NASDAQ:NBP) is a biotech company focused on developing immuno-oncology agents for cancer tre ...